Salud financiera de hoja de balance de Relay Therapeutics
Salud financiera controles de criterios 6/6
Relay Therapeutics tiene un patrimonio de los accionistas total de $752.0M y una deuda total de $0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son $844.0M y $92.0M respectivamente.
Información clave
0%
Ratio deuda-patrimonio
US$0
Deuda
| Ratio de cobertura de intereses | n/a |
| Efectivo | US$750.09m |
| Patrimonio | US$752.00m |
| Total pasivo | US$91.98m |
| Activos totales | US$843.98m |
Actualizaciones recientes sobre salud financiera
We Think Relay Therapeutics (NASDAQ:RLAY) Can Afford To Drive Business Growth
Nov 14
Will Relay Therapeutics (NASDAQ:RLAY) Spend Its Cash Wisely?
Jun 08Is Relay Therapeutics (NASDAQ:RLAY) In A Good Position To Invest In Growth?
Feb 22Is Relay Therapeutics (NASDAQ:RLAY) In A Good Position To Invest In Growth?
Oct 23Relay Therapeutics (NASDAQ:RLAY) Is In A Strong Position To Grow Its Business
Mar 26Relay Therapeutics (NASDAQ:RLAY) Is In A Strong Position To Grow Its Business
Dec 08
Recent updates
Relay Therapeutics, Inc. (NASDAQ:RLAY) Analysts Just Trimmed Their Revenue Forecasts By 12%
Apr 17Relay Therapeutics: Platform More Important Than Programs
Mar 13Relay Therapeutics: Tapping Into An Unmet Need At A High Price Tag
Feb 13Analyst Forecasts Just Became More Bearish On Relay Therapeutics, Inc. (NASDAQ:RLAY)
Jan 21We Think Relay Therapeutics (NASDAQ:RLAY) Can Afford To Drive Business Growth
Nov 14Will Relay Therapeutics (NASDAQ:RLAY) Spend Its Cash Wisely?
Jun 08Is Relay Therapeutics (NASDAQ:RLAY) In A Good Position To Invest In Growth?
Feb 22Is Relay Therapeutics (NASDAQ:RLAY) In A Good Position To Invest In Growth?
Oct 23Relay set to Equal Weight at Barclays; says fairly valued ahead of catalysts
Sep 30Relay Therapeutics: Bile Duct Cancer Approval Shot Validates Pricey Platform
Sep 18Why did Relay Therapeutics stock drop today?
Sep 09Estimating The Fair Value Of Relay Therapeutics, Inc. (NASDAQ:RLAY)
Jan 02Relay Therapeutics, Inc. (NASDAQ:RLAY) Analysts Are Reducing Their Forecasts For This Year
Aug 17Relay Therapeutics, Inc. (NASDAQ:RLAY) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates
May 16Relay Therapeutics (NASDAQ:RLAY) Is In A Strong Position To Grow Its Business
Mar 26Read This Before Selling Relay Therapeutics, Inc. (NASDAQ:RLAY) Shares
Feb 01Relay Therapeutics inks deal for RLY-1971 with Genentech
Dec 14Relay Therapeutics (NASDAQ:RLAY) Is In A Strong Position To Grow Its Business
Dec 08Relay Therapeutics reports Q3 results
Nov 12Análisis de la situación financiera
Pasivos a corto plazo: Los activos a corto plazo ($770.1M) de RLAY superan a sus pasivos a corto plazo ($30.3M).
Pasivo a largo plazo: Los activos a corto plazo de RLAY ($770.1M) superan a sus pasivos a largo plazo ($61.7M).
Historial y análisis de deuda-patrimonio
Nivel de deuda: RLAY está libre de deudas.
Reducción de la deuda: RLAY no ha tenido ninguna deuda en los últimos 5 años.
Hoja de balance
Análisis de cash runway
En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.
Cash runway estable: RLAY tiene suficiente cash runway para más de un año basándose en su flujo de caja libre actual.
Pronóstico de cash runway: RLAY dispone de suficiente cash runway para 2.9 años si el flujo de caja libre sigue reduciéndose a tasas históricas de 38.9% cada año.